# GPCRs and Trimeric G Proteins

> GPCR subtype, G protein, and downstream proteins decide the first response. Follow an agonist's effect from a seven-pass receptor through nucleotide exchange on a trimeric G protein, then use the four Gα families and the βγ pair to predict what a cell does next. Finally, use basal activity to distinguish an agonist, a neutral antagonist and an inverse agonist.

Course: Cell Signaling (G-protein-coupled receptors and second messengers). Level: advanced university and graduate. About 14 minutes.
Lesson page (link this one when citing): https://stemhop.com/lessons/gpcrs-and-g-proteins/

Builds on: A Field Guide to Receptors · Binding: Affinity, Occupancy and Dose–Response · GTPase Switches: The Timer

## What you'll learn

- Describe the seven-pass receptor and what an agonist changes in it so that a G protein can dock.
- Name the four families of Gα (Gs, Gi/o, Gq/11, G12/13), the main target of each, and one job of the βγ pair.
- Explain how one hormone gives opposite answers in two tissues: GPCR subtype, G protein, and downstream proteins decide the first response.
- Tell apart an agonist, an antagonist and an inverse agonist at a receptor with some activity of its own, and say what pertussis toxin does.

Adrenaline makes the heart beat harder, relaxes airway muscle and narrows skin blood vessels. The hormone matters, but it cannot specify those opposite outcomes by itself.

> **The one idea.** G-protein-coupled receptor (GPCR) subtype, G protein, and downstream proteins decide the first response.
>
> *Scope:* the first response through the canonical GPCR–heterotrimeric-G-protein pathway in a particular cell. Ligand dose and efficacy still matter, one receptor may use several G proteins, and prolonged signaling recruits other partners.

## From an outside pocket to an inside switch

The first film drew this relay as cartoons; here are the real parts.

A **G-protein-coupled receptor (GPCR)** is one protein chain that crosses the plasma membrane seven times. Each crossing is an alpha helix of twenty or more mostly water-avoiding amino acids. The amino end lies outside the cell and the carboxyl end inside, the architecture from the receptor field guide.

**“Lots of inputs/ligands.”** The fold accepts very different inputs: adrenaline, acetylcholine, dopamine, histamine, glucagon and other peptide hormones, odorants, bitter and sweet tastes, and light. Roughly a third of approved drugs act on a GPCR.

An **agonist** activates its receptor (the lesson on binding and dose-response). In the beta-2-adrenergic receptor, adrenaline binds among the helices toward the outer face. Comparing the receptor’s inactive [crystal structure](https://stemhop.com/methods/x-ray-crystallography/) with one caught holding Gs (with a high-affinity agonist bound) shows the largest change inside: the cytoplasmic end of helix 6 moves outward by about 14 angstroms, opening the cavity where the tail of G alpha docks.

The **heterotrimeric G protein** has three subunits. G alpha holds a guanine nucleotide; G beta and G gamma bind so tightly that they act as one beta-gamma unit. Lipid tails on G alpha and G gamma hold the trio at the membrane’s inner face, as in the lesson on lipid anchors.

The active receptor acts as a **guanine-nucleotide exchange factor (GEF)**: it promotes GDP release from G alpha, and GTP, more plentiful than GDP in the cytosol, fills the empty site. In the textbook picture G-alpha–GTP then leaves beta-gamma; in living cells, activated Gi may instead rearrange without fully separating.

> **active receptor + Gα(GDP)·βγ + GTP → active receptor + Gα(GTP) + βγ + GDP**

The receptor appears on both sides because it is a catalyst, the source of the gain from the lesson on signaling circuits. One activation cycle ends when G alpha hydrolyses GTP and the GDP-bound trimer reforms.

**Predict.** A mutant G alpha can bind GDP but cannot release it. The receptor still binds agonist. What happens to the first downstream response?

> **Check your prediction.** It fails. The receptor activates, but G alpha cannot release GDP to load GTP, so the G protein stays inactive.

## ”All the pathways”: four G-alpha families, then many targets

The human genome has 16 G-alpha genes in four sequence families.

| G-alpha family | Main direct target | First consequence | Example receptors |
| --- | --- | --- | --- |
| Gs | adenylyl cyclase, activated | cAMP rises | beta-adrenergic, glucagon |
| Gi/o | adenylyl cyclase, inhibited | cAMP falls; beta-gamma acts | M2 muscarinic, alpha-2-adrenergic, CB1 cannabinoid |
| Gq/11 | phospholipase C-beta | PIP2 becomes IP3 and DAG; calcium rises | alpha-1-adrenergic, M3 muscarinic |
| G12/13 | exchange factors for Rho | actin rearranges; cells change shape and move | thrombin, lysophosphatidic acid |

Beta-gamma is a signal too: in heart pacemaker cells, beta-gamma released from Gi opens the GIRK potassium channel, short for G-protein-gated inwardly rectifying potassium channel. Potassium flows out and moves the membrane potential away from the firing threshold. G-alpha-i also lowers cAMP, reducing current through pacemaker channels that cAMP opens directly.

**“Lots of downstream effectors.”** This is the hourglass the first film drew.

*Figure (AI-generated illustration).* Many GPCRs narrow to four G-alpha families and beta-gamma, then fan out to distinct enzymes and ion channels. Image: a schematic pathway overview links many GPCRs to four Galpha families and the beta-gamma pair. Detail panels show selected targets: Galpha-s stimulates and Galpha-i inhibits adenylyl cyclase; Galpha-q/11 activates phospholipase C-beta; Galpha-12/13 activates exchange factors for Rho; and beta-gamma opens a GIRK potassium channel.

**Predict.** A receptor agonist lowers cAMP. Pertussis toxin leaves basal cAMP unchanged but prevents that fall. Which family carried the response?

> **Check your prediction.** Gi/o. Pertussis toxin, an enzyme from the whooping-cough bacterium, adds ADP-ribose to a cysteine near the tail of G alpha-i and G alpha-o, so the tail cannot engage the receptor and the protein stays GDP-bound. Cholera toxin, from the lesson on GTPase switches, instead jams Gs on.

If pertussis toxin abolishes a response, that response most likely runs through Gi/o. The reverse test is weaker: Gz, a Gi/o-family member, lacks the toxin site, so toxin resistance does not exclude that family.

*Figure (AI-generated illustration).* Pertussis toxin prevents susceptible Gi/o proteins from engaging their receptor, so they remain GDP-bound and the response disappears. Image: two matching views of a receptor and its Gi protein. In the normal view the tail of G alpha-i fits the receptor's cavity. In the pertussis toxin view a gold ADP-ribose tag sits on the tail, which no longer fits, so the G protein stays with GDP bound.

## One ligand, different cellular answers

The first film traced acetylcholine: through M2 and Gi it slows pacemaker cells, and through M3 and Gq it contracts airway muscle. One transmitter quiets one tissue and excites another. Acetylcholine also marks the rule’s boundary: at skeletal muscle it meets an ion channel from the receptor field guide, not a G-protein-coupled receptor (GPCR).

Adrenaline has a larger cast: nine human adrenergic receptor genes. Three alpha-1 subtypes couple mainly to Gq, three alpha-2 subtypes to Gi, and three beta subtypes to Gs.

**Predict.** Assign one adrenergic subtype and G-alpha family to make the heart beat harder, relax airway muscle and narrow skin vessels. Then predict the effect of blocking only the heart subtype.

> **Check your prediction.** Skin vessels: alpha-1 on Gq, because raised cytosolic calcium contracts smooth muscle. Airway muscle: beta-2 on Gs, because raised cAMP favors relaxation there. Heart: beta-1 on Gs. Heart and airway cells interpret the same messenger differently because different downstream proteins wait for cAMP (the next lesson follows that messenger).
>
> Blocking only beta-1, the reasoning behind beta-1-selective beta-blockers, lowers heartbeat rate and force during adrenaline signaling and leaves airway and vessel receptors alone. A blocker that also hits beta-2 removes adrenaline’s airway relaxation, a risk for a person with asthma. This is the assignment the body mainly uses.

**Predict.** The thrombin receptor on platelets activates both Gq and G12/13. If a drug blocked only the Gq branch, which output in the table could remain?

> **Check your prediction.** The G12/13 branch could still activate Rho exchange factors and reshape the cell, even if the Gq-dependent calcium rise were lost.

So far ligands have only switched receptors on. But efficacy, how far a bound ligand moves the response, can also push it below where it started.

**Film transcript: Above, At, or Below Basal**

### Film transcript: Above, At, or Below Basal

The first film followed a receptor as it loaded a G protein. If an empty receptor already signals, where can a ligand move the response? A receptor population can signal even when every binding pocket is empty. Individual receptors sample less-active and more-active shapes. If some active shapes engage G proteins, the population produces basal activity. That starting signal becomes the reference for classifying what a ligand does. An agonist raises signaling above that line. In the simple picture, it favors the more-active receptor population. Gold agonist blocks settle into open receptor pockets. More receptors remain signaling-competent, so the meter rises.

Agonist describes the measured effect, not merely the ability to bind. A neutral antagonist behaves differently. By itself, it leaves basal signaling approximately unchanged. Its job appears when another ligand arrives. Antagonist blocks occupy the pockets, so the incoming agonist finds few free receptors. At this agonist dose, the meter stays near basal instead of rising. Neutral describes the drug's effect on basal activity. An inverse agonist moves the response below basal. In the simple picture, it favors the less-active receptor population. Red-edged ligand blocks settle into those receptors. Fewer receptors engage G proteins, and the meter falls.

The prefix inverse refers to signaling direction, not to opposite binding. Now remove measurable basal activity from the assay. The meter starts at zero. A neutral antagonist cannot lower it. Neither can an inverse agonist reveal a further decrease. Added alone, they look the same. Distinguishing them requires a receptor system with a visible basal signal. Real ligands can produce intermediate changes, even at a saturating concentration.

Carazolol, bound in inactive β2-adrenergic receptor structures, is a partial inverse agonist. In an assay, it lowers basal signaling without producing the full reduction possible there. Efficacy means the response a bound ligand can produce. Partial describes its efficacy in that measured pathway, not incomplete binding in this assay. The active-versus-inactive picture is a useful first model, not a claim of only two rigid structures. Receptors sample ensembles of shapes. Efficacy is measured for one response in one cell. A ligand classed in one assay may class differently in another. Keep the meter and assay beside the receptor whenever you name efficacy.

Use one reference line and three questions. Does the ligand raise signaling above basal? Does it leave basal unchanged while blocking another ligand? Or does it lower signaling below basal? Those observations separate agonism, neutral antagonism, and inverse agonism without pretending the receptor is a simple switch.

From the film

- Basal activity separates agonists, neutral antagonists, and inverse agonists.
- An agonist raises signaling above basal activity.
- A neutral antagonist leaves basal activity unchanged while blocking other ligands.
- An inverse agonist lowers signaling below basal activity.

## Ligand efficacy, and why “GPCRs can be unfaithful to trimeric G proteins”

The second film classed ligands by how they move **basal activity**, a receptor population’s signaling with no ligand: an **agonist** raises it, a neutral **antagonist** leaves it while blocking other ligands, an **inverse agonist** lowers it. Its meter was an operational test, not a claim that a G-protein-coupled receptor (GPCR) has only two rigid structures.

For many receptors only a small fraction is active at any moment, so basal activity can be too low to measure. Many drugs long called antagonists proved to be inverse agonists once tested where it was visible. Carazolol, the beta-blocker bound in the inactive beta-2 receptor structures from 2007, is a partial inverse agonist.

The four-family table also simplified: as the thrombin receptor showed, one receptor can couple to several G-alpha families, and the dominant partner can differ between cell types, so a coupling measured in one cell line is a hypothesis about the next. Efficacy is measured the same way: a ligand classed for one response in one cell may be classed differently for another.

Time adds another partner. Kinases phosphorylate a receptor that has stayed active, then **arrestin** binds its tail, blocks further G-protein coupling and helps pull the receptor into the cell. It also binds other signaling proteins, but whether arrestin signals on its own without G proteins remains debated, a question the lesson on turning signals off develops.

**Predict.** Two cell lines have equal amounts of a Gs-coupled receptor known to undergo beta-arrestin-dependent desensitization, such as the beta-2-adrenergic receptor, but one lacks both beta-arrestins. After prolonged agonist exposure, which line should retain more G-protein signaling?

> **Check your prediction.** The line lacking beta-arrestins. Its initial response can be normal, but it loses a major brake on repeated receptor–G-protein coupling, so desensitization is reduced.

## Going deeper

### How the seven-pass plan was found

Rhodopsin, the light-catching pigment of retinal rod cells, was too greasy to sequence whole. Paul Hargrave’s laboratory in the United States and Yuri Ovchinnikov’s in Moscow cut it at methionine and sequenced the pieces one amino acid at a time. By 1983 both had published the complete cow-rhodopsin sequence, including seven water-avoiding stretches long enough to span a membrane.

In 1986 Robert Lefkowitz’s laboratory at Duke and a Merck group cloned a beta-adrenergic receptor gene. Brian Kobilka, then a cardiology fellow, had worked toward it for almost two years. Its sequence resembled rhodopsin, seven spans included. The only other seven-pass protein then known also used light, and Lefkowitz later recalled speculation that this plan marked light-sensitive molecules. The adrenaline receptor showed instead that it marked receptors that signal through G proteins.

### How many GPCR genes

The human genome holds roughly 800 G-protein-coupled receptor (GPCR) genes; Lefkowitz’s Nobel lecture says almost a thousand. About half are odorant receptors, while a mouse has about a thousand odorant-receptor genes alone.

### How the pertussis test named CB1

An **orphan receptor** is a receptor gene with no known ligand. In 1990 Lisa Matsuda and colleagues in Tom Bonner’s group had a rat-brain gene predicting a seven-pass protein. Allyn Howlett’s laboratory had shown that cannabinoids lower cAMP dose-dependently in nerve-cell preparations, that only one mirror-image form works, and that pertussis toxin blocks the effect. Expressed in cells that lacked it, the orphan showed those properties: it was CB1, the cannabinoid receptor, which couples to Gi/o.

---

From STEMhop (https://stemhop.com), free lessons by Christopher Deppmann. Lesson text © the authors. Practice questions: https://stemhop.com/lessons/gpcrs-and-g-proteins/
